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a b s t r a c t 
Tuberculosis-immune reconstitution inﬂammatory syndrome is an excessive immune response against 
Mycobacterium tuberculosis that may occur in either HIV-infected or uninfected patients, during or after 
completion of anti-TB therapy. In HIV-infected patients it occurs after initiation of antiretroviral therapy 
independently from an effective suppression of HIV viremia. There are two forms of IRIS: paradoxical or 
unmasking. Paradoxical IRIS is characterized by recurrent, new, or worsening symptoms of a treated case. 
Unmasking IRIS is an antiretroviral-associated inﬂammatory manifestation of a subclinical infection with 
a hastened presentation. The pathogenesis is incompletely understood and the epidemiology partially 
described. No speciﬁc tests can establish or rule out the diagnosis. Treatment is based on the use of 
anti-tuberculosis drugs sometime with adjunctive corticosteroids. Mortality is generally low. 
© 2016 Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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tIntroduction 
Tuberculosis-immune reconstitution inﬂammatory syndrome
(TB-IRIS) is an abnormal, excessive immune response against
alive or dead Mycobacteria tuberculosis that may occur in either
HIV-infected or, more rarely, uninfected patients. In HIV-infected
patients it occurs after initiation of antiretroviral therapy inde-
pendently of an effective suppression of HIV viremia. Paradoxical
worsening of tuberculosis in HIV-uninfected patients was indeed
ﬁrst described after introduction of antituberculous drugs in 1954
[1] . This review summarizes the available literature on epidemi-
ology, pathogenic mechanisms, diagnosis, clinical manifestations,
and treatment options of TB-IRIS. 
Deﬁnition of TB-IRIS 
TB-IRIS is a paradoxical worsening or recurring of preexisting
tuberculous lesions, or a development of new lesions in patients
on effective antituberculosis treatment. It may occur during or
even after completion of anti-TB therapy. TB-IRIS might be mis-
diagnosed as superimposed infections, treatment failure following
inadequate anti-TB treatment, drug-resistant TB, or TB relapse
[2, 3] . Therefore, the following strict criteria must be applied to
diagnose TB-IRIS [4] : ∗ Corresponding author: Tel.: + 7 7172 694654. 
E-mail address: ventosandro@yahoo.it (S. Vento). 
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2405-5794/© 2016 Published by Elsevier Ltd. This is an open access article under the CC(1) initial improvement of TB-related symptoms and/or radio-
graphic ﬁndings after adequate anti-TB treatment for a cer-
tain time; 
(2) paradoxical deterioration of TB-related symptoms and/or ra-
diologic ﬁndings at the primary or at new locations during
or after anti-TB treatment; 
(3) absence of conditions that reduce the eﬃcacy of anti-TB
drugs (e.g., poor compliance, drug malabsorption, drugs side
effects); 
(4) exclusion of other possible causes of clinical deterioration. 
In an attempt to develop diagnostic criteria, various deﬁnitions
f IRIS were developed in HIV-infected patients, including those
roposed by Shelburne et al. [5] , French et al. [6] , and Robertson
t al. [7] . In 2008 a consensus deﬁnition for TB-associated IRIS
as created for resource poor-settings [8] in order to have a stan-
ardized case deﬁnition which could assist in diagnosing TB-IRIS
n countries with limited resources. 
There are two forms of IRIS: paradoxical or unmasking. Para-
oxical IRIS is deﬁned as recurrent, new, or worsening symp-
oms of a treated case. Unmasking IRIS is an antiretroviral (ART)-
ssociated inﬂammatory manifestation of a subclinical infection
ith a hastened presentation. In this latter form signs and symp-
oms not clinically apparent before, appear during ART. 
pidemiology 
Different studies have estimated the frequency of TB-IRIS
etween 2% and 23% [3,9,10–13] in HIV-uninfected patients. InBY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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cIV-infected patients a retrospective meta-analysis of 54 cohorts
howed that the incidence of TB-IRIS in patients on ART treatment
as 15.7% with a mortality of 3.2% [14] . Neurological TB-IRIS
ccurred in 12% of TB-IRIS cases in a single center in a TB endemic
rea [15] . Nonetheless the frequency of tuberculosis-associated
RIS remains diﬃcult to assess because of the heterogeneity of
he deﬁnitions. Risk factors for a paradoxical response include
isseminated tuberculosis [8] , young age, male gender, anemia [4] ,
ymphopenia or a CD4 + T lymphocyte count less than 50 /mm 3 ,
se of biological agents (e.g., anti-TNF α), and a marked increase
n lymphocyte count or suppression of HIV-RNA replication with
ntiretroviral therapy [8,13] . The median time to onset of the
aradoxical response was 21–56 days after initiation of antituber-
ulous treatment in HIV-uninfected patients [13] , and two–four
eeks in HIV-infected patients on antiretroviral therapy [8] . The
verall mortality in patients with a paradoxical response has been
stimated at 3% [14] . 
athogenesis 
The immunopathogenesis of IRIS remains only partially under-
tood. Qualitative and quantitative reconstitution of the immune
ystem, host genetic susceptibility and mycobacterial load are sup-
osedly involved in the pathogenesis of IRIS. 
The role of the amount of mycobacteria in the pathogenesis is
uggested by several observations. In patients with disseminated or
xtrapulmonary tuberculosis the increased risk of IRIS is attributed
o a higher bacillary load [2,3] . In HIV-positive patients, the risk
f IRIS is highest if the antiretroviral therapy is initiated early dur-
ng antimycobacterial treatment, when the mycobacterial load is
onsiderable [16] , as shown in trials trying to establish the correct
ime of ART initiation [17–19] . 
The hasty killing of mycobacteria by anti-TB therapy may de-
ermine the release of large amounts of mycobacterial antigens,
hich can stimulate an excessive inﬂammatory response [20] . A
rospective study recently showed a correlation between positive
putum culture (indicating high antigenic load) and inﬂammatory
onocyte activation markers (strongly predictive of development
f paradoxical TB-IRIS), suggesting that high antigen loads and in-
ammation may act together in the pathogenesis [21] . However
ost inﬂammatory responses (with the release of proinﬂamma-
ory cytokines) may be stronger determinants of IRIS pathogene-
is than mycobacterial factors [22] . Other studies also indicate that
mmune reconstitution is involved in the pathogenesis of IRIS, and
n particular the reconstitution of T helper 1 CD4 + immune re-
ponses, as shown by the conversion of tuberculin skin tests to
ositive after treatment start [2,11] . ART initiation has been associ-
ted with a shift from T helper 2 to T helper 1 cytokine patterns,
nd with the restoration of T lymphocyte proliferative responses
23] . 
In conclusion, the immunopathogenesis of IRIS in both HIV-
nfected and uninfected patients appears to involve T helper 1-
riven immune responses in the presence of multibacillary disease
nd immunodeﬁciency. 
linical manifestations 
TB-IRIS in HIV-uninfected patients is more frequent in extra-
ulmonary (especially in pleural and lymph node forms) than in
ulmonary TB. The median time to IRIS onset after starting anti-
B drugs is generally up to three months. The most frequent pre-
enting symptoms of TB-IRIS are recurrent fever, enlarged lymph
odes and worsening dyspnea [2] . The principal sites involved in
B-IRIS are lymph nodes (68%) and lungs (16%), independently of
he sites of primary tuberculosis [4] . Thoracic TB-IRIS manifest asew pulmonary parenchymal lesions [24,25] , development of new
ymphadenopathy or increase in the size of a preexisting lym-
hadenopathy [2,9,25,26] , development of new or progression of
reexisting pleural effusions [27,28] , new endobronchial lesions.
B-IRIS usually develops on the same side of primary TB, though
ontralateral or bilateral lesions can also occur [24] . 
Development of new lymphadenopathy or enlargement of
reexisting lymph nodes can be observed in up to 25% of
IV-uninfected patients with peripheral TB lymphadenitis [3] . The
edian time to development is generally 4–14 weeks after the ini-
iation of anti-TB treatment but can also be longer (1–13 months
fter treatment completion) [9,26] . In patients with pleural TB
ew peripheral pulmonary lesions occur in 2.4%–11%, developing
–9 months after the beginning of anti-TB therapy [25] . 
Pleural TB-IRIS (manifesting as a new or increased pleural effu-
ion) happens in 16%–45% of HIV-uninfected patients with pleural
27,28] , lymph node [25] , or pulmonary TB [3] . It generally devel-
ps within 3–19 weeks of treatment initiation [28] . 
In patients with miliary or disseminated TB the occurrence of
oft tissue TB-IRIS (presenting as new inﬂammatory or non inﬂam-
atory lesions within the skin or subcutaneous tissues) is more
requent than in those with pleural or lymph node TB [29, 30] .
ndobronchial TB-IRIS, manifesting as partial or totally obstructive
esions, is rare and can be due either to a ﬁstulation or erosion of
 lymph node into a bronchus or a de novo endobronchial reaction
31] . 
TB-IRIS in HIV-infected patients is one of the most common
orms of IRIS and occurs in 15.7% of TB patients starting ART
ccording to Müller’s meta-analysis [14] . However some studies
eport higher rates; for instance, a 54.2% incidence was reported in
atients with culture-conﬁrmed pulmonary TB in India [32] , and
 47% incidence of paradoxical TB-IRIS was found in South African
atients with TB meningitis [15] , determining a considerable
isease burden [33] . 
Although both paradoxical and unmasking forms of TB-IRIS
ave been reported in HIV-infected individuals, paradoxical IRIS
as been more extensively and better studied. In patients with pul-
onary tuberculosis, paradoxical TB-IRIS presents as a worsening
r recurrence of respiratory (shortness of breath, cough) and con-
titutional symptoms (fever, weight loss, night sweats), and often
ew or expanding inﬁltrates on chest X-ray images [34] . Lymph
ode paradoxical IRIS generally presents with rapid enlargement
ollowed by suppuration [35] . 
Paradoxical neurologic TB-IRIS is a possibly life threatening con-
ition and symptoms tend to manifest later than in forms not in-
olving the central nervous system, generally 5-10 months after
RT initiation. Neurologic TB-IRIS generally presents with new or
orsening meningitis and/or features of raised intracranial pres-
ure, due to enlarging cerebral tuberculomas or intracranial ab-
cesses; mortality is high and ranges from 12% to 25% [36–38] . It
ay also present with spondylitis, epidural abscesses, and radicu-
omyelopathy [15,38] . 
Abdominal TB-IRIS can occur as granulomatous hepatitis,
etroperitoneal lymphadenopathy, and peritonitis, whereas the 
usculoskeletal form manifests as mono- or polyarthritis [39] . 
‘Unmasking TB-IRIS’ is not as well deﬁned as “paradoxical TB-
RIS” and refers to a form of TB that becomes clinically recog-
izable after the initiation of ART and presents with exaggerated
nﬂammatory features. It usually develops within the ﬁrst three
onths of ART. Unmasking TB-IRIS forms can vary widely in the
egree of clinical presentation, often with features indistinguish-
ble from those of paradoxical TB-IRIS. Two-thirds of unmasking
orms present with lung involvement (often severe pulmonary tu-
erculosis leading to acute respiratory distress syndrome, or bron-
hiolitis obliterans organizing pneumonia) [40, 41] . 
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 Diagnosis 
No speciﬁc tests can establish or rule out the diagnosis of TB-
IRIS that must take into consideration a combination of clinical
signs and symptoms, and laboratory ﬁndings. The following clinical
features suggest a diagnosis of TB-IRIS: improvement of symptoms
on TB treatment prior to initiating ART, deterioration of symptoms
soon after starting ART, and exclusion of alternative causes for clin-
ical deterioration. 
The differential diagnosis of TB-IRIS must include poor adher-
ence or malabsorption of antituberculous therapy, drug reactions,
drug-resistant tuberculosis, malignancies, and other opportunistic
or bacterial infections [42] . In a South African study, the most com-
mon alternative diagnosis was drug-resistant TB [42] . 
Treatment 
There is no consensus yet on the standard treatment of TB-
IRIS. Approximately half of the cases of lymph node TB-IRIS re-
solve spontaneously [25] . In some patients with lymph node, air-
ways or soft tissue TB-IRIS, prolonged antituberculosis treatment
may be required. However the optimal treatment duration is un-
clear. Most patients with TB-IRIS show clinical improvement in
the two months following antituberculosis treatment [3] but the
range is wide (1–7 months) [3] . After 3–18 months of anti-TB treat-
ment, pulmonary lesions and lymphadenopathy generally disap-
pears. Again, the time needed for complete resolution is variable,
and there may be residual lesions. 
Depending on sites and severity of TB-IRIS, adjunctive therapy
may be necessary. For instance, patients with soft-tissue abscesses
or symptomatic pleural effusions often require aspiration [28] . Sys-
temic corticosteroid administration for four–six weeks improves
the outcome of certain forms of TB-IRIS (symptomatic enlarging
intracranial tuberculoma, endobronchial obstruction) and reduces
proinﬂammatory cytokines [31,43,44] . However, its role in other
forms of TB-IRIS is unclear. Corticosteroids and nonsteroidal anti-
inﬂammatory drugs have been used to treat IRIS, although only
for corticosteroids a double blind, randomized, placebo-controlled
clinical trial was performed in patients with paradoxical TB-IRIS
[45] . Prednisone signiﬁcantly reduced days of hospitalization and
outpatient therapeutic procedures, more rapidly improving symp-
toms, quality-of life score and chest radiography [45] . For most pa-
tients a four-week course of prednisone reduced morbidity from
TB-IRIS. There was no difference in mortality between prednisone
and placebo-treated participants, even though cases with neuro-
logical involvement were excluded from the trial. Minor infections
(oral candidiasis and uncomplicated herpes simplex) were more
common in patients on prednisone. Most authors suggest treat-
ment with corticosteroids for a maximum of four-six months. 
In HIV-positive patients already on ART, antiretroviral therapy
generally must be continued. In patients with active tuberculosis
the timing to start ART has been established; early initiation of
ART (within two–four weeks after the initiation of antituberculous
therapy) in patients with CD4 counts below 50 /mm 3 leads to de-
creased rates of AIDS-associated comorbidities and mortality even
though there is an increased risk of IRIS events, when compared
with patients who start therapy later [46] . Indeed the SAPiT trial
showed that in patients with CD4 counts < 50 /mm 3 , the early
therapy group (ART started around two weeks after TB treatment)
had an IRIS incidence rate of 45.5, as compared with 9.7 among
patients who started therapy three–four months after initiation of
antituberculous therapy [47] . Even though deaths were associated
with IRIS in both the SAPiT trial and the CAMELIA trial [48] , the
beneﬁt in terms of reduced mortality continued to favor early
therapy. In patients with pulmonary TB and a CD4 cell count higher than
0 /mm 3 , ART can be initiated eight weeks after starting antituber-
ulosis treatment without excess mortality. It remains to be seen
hether patients with TB of the central nervous system would rep-
esent a subpopulation at increased risk of IRIS death. 
Tuberculous meningitis is the most severe form of TB with a
oor prognosis in HIV-infected persons, independently of ART use
49] . Neurological TB-IRIS (manifesting as meningitis, intracranial
uberculomata, brain abscesses, radiculomyelitis, and spinal epidu-
al abscesses) contributes to this poor outcome. 
Oral or intravenous corticosteroids have shown beneﬁt in some
ases of neurologic TB-IRIS [49] . In HIV-infected patients with neu-
ological TB-IRIS unresponsive to corticosteroids and with a de-
ressed level of consciousness, temporary interruption of ART may
e considered. If ART has not been started yet, a delayed initiation
f antiretroviral therapy can be considered [50] . 
onclusions 
TB-IRIS (paradoxical and unmasking forms) constitutes a
pectrum of clinical presentations that can occur during Mycobac-
erium tuberculosis infection. Mortality is generally low both in
IV-infected and uninfected patients. More studies are needed
o elucidate the pathogenesis and establish better treatment
odalities. 
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